Scientific Motivation

Breakthroughs in cancer research within the last decade have revolutionised our understanding of the molecular pathology of cancer. Nevertheless, the success of most of the currently available targeted cancer therapies is limited and the development of novel treatment options is slow. To accelerate the translation of research findings to novel therapeutics, the German Cancer Research Center and Bayer HealthCare have joined forces and set up a strategic alliance in 2008. The Symposium is held within the framework of this partnership and is the second of its kind. It will bring together preclinical and clinical scientists as well as pharma researchers to present their recent findings relevant to the identification of novel targets or the development of novel therapeutic strategies.

The goal is to discuss established and emerging targeted cancer therapies. Scientific and clinical aspects will be reviewed in the context of onco-genomics, cancer stem cells, and immunotherapy.

We cordially invite you to the stimulating environment and “scientific hot spot” of Heidelberg to discuss with us options to translate scientific ideas to novel treatment options.

Scientific Organizing Committee
# Programme

### Monday, November 19, 2012

**Opening**

<table>
<thead>
<tr>
<th>Time</th>
<th>Name</th>
<th>Position and Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>Otmar Wiestler</strong></td>
<td>Chairman and Scientific Director, German Cancer Research Center (DKFZ), Heidelberg</td>
<td>Welcome address</td>
</tr>
<tr>
<td>14:15</td>
<td><strong>Andreas Busch</strong></td>
<td>Head of Global Drug Discovery, Bayer Healthcare</td>
<td>Welcome address</td>
</tr>
<tr>
<td>14:30</td>
<td><strong>Douglas Hanahan</strong></td>
<td>Swiss Institute for Experimental Cancer Research (ISREC), EPFL, Lausanne, Switzerland</td>
<td>Keynote lecture I: Lessons in translational oncology from mouse models of cancer.</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

**Session I: Oncogenomics.**  
Chairs: Peter Lichter, Volker Gekeler

<table>
<thead>
<tr>
<th>Time</th>
<th>Name</th>
<th>Position and Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td><strong>Ewan Birney</strong></td>
<td>European Bioinformatics Institute (EBI), Hinxton, UK</td>
<td>ENCODE: an initial systematic analysis of non-coding DNA.</td>
</tr>
<tr>
<td>16:30</td>
<td><strong>Mark A. Rubin</strong></td>
<td>Weill Cornell Medical College, New York, USA</td>
<td>First steps in precision medicine for prostate cancer: defining molecular subclasses.</td>
</tr>
</tbody>
</table>

**Tuesday, November 20, 2012**

**Session II: Cancer Stem Cells.**  
Chairs: Andreas Trumpp, Dominik Mumberg

<table>
<thead>
<tr>
<th>Time</th>
<th>Name</th>
<th>Position and Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td><strong>Eduard Batlle</strong></td>
<td>Institute for Research in Biomedicine (IRB), Barcelona, Spain</td>
<td>From colon stem cells to colorectal cancer.</td>
</tr>
<tr>
<td>9:30</td>
<td><strong>Ravi Majeti</strong></td>
<td>Stanford University Cancer Center, California, USA</td>
<td>Targeting CD47 with blocking monoclonal antibodies in human hematologic malignancies.</td>
</tr>
<tr>
<td>10:00</td>
<td><strong>Jörg Hüsken</strong></td>
<td>Swiss Institute for Experimental Cancer Research (ISREC), EPFL, Lausanne, Switzerland</td>
<td>Metastatic colonization: new opportunities for therapeutic intervention.</td>
</tr>
<tr>
<td>10:30</td>
<td><strong>Tim Hoey</strong></td>
<td>OncoMed Pharmaceuticals, Redwood City, California, USA</td>
<td>Development of OMP-18R5, a novel Wnt signaling antagonist that reduces cancer stem cell frequency.</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

**Session III: Immunotherapy.**  
Chairs: Philipp Beckhove, Bertolt Kreft

<table>
<thead>
<tr>
<th>Time</th>
<th>Name</th>
<th>Position and Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td><strong>Thomas F. Gajewski</strong></td>
<td>University of Chicago, USA</td>
<td>Immunotherapeutic targets for melanoma identified through interrogation of the tumor microenvironment.</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td>Lunch reception</td>
</tr>
<tr>
<td>14:00</td>
<td><strong>Hansjörg Schild</strong></td>
<td>Institute for Immunology, University Medical Center Mainz, Germany</td>
<td>Mechanisms controlling the stimulatory capacity of dendritic cells.</td>
</tr>
<tr>
<td>14:30</td>
<td><strong>Laurence Zitvogel</strong></td>
<td>Institut Gustave Roussy, Villejuif, France</td>
<td>Immuno-on target effects of anticancer therapies.</td>
</tr>
<tr>
<td>15:00</td>
<td><strong>Benno Rattel</strong></td>
<td>Amgen Research, Munich, Germany</td>
<td>Immunotherapy with BiTE antibodies: lessons learned from blinatumomab.</td>
</tr>
<tr>
<td>15:30</td>
<td><strong>Alexander Lesokhin</strong></td>
<td>Memorial Sloan-Kettering Cancer Center, New York, USA</td>
<td>Biomarkers of response to ipilimumab.</td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td>End of symposium</td>
</tr>
</tbody>
</table>